Why it matters
AIM-SAFE aims to develop a new generation of artificial intelligence (AI) tools to improve medication safety and support healthcare professionals in making more informed treatment decisions, particularly in complex areas such as cancer care and elderly patients taking multiple medicines. Today, doctors and pharmacists must manage huge amounts of medical information, including drug interactions, patient histories, genetics, and constantly evolving clinical guidelines, often within very limited consultation times. This can increase the risk of medication errors, harmful side effects and ineffective treatments. AIM-SAFE aims to reduce these risks by creating a “Safety Co-Pilot”, an AI-powered assistant that works alongside healthcare professionals to analyse different types of patient information and provide transparent, evidence-based recommendations. AIM-SAFE will focus on three major real-world challenges: improving medication safety for older patients aged 65+ with multimorbidity and taking more than four medications, supporting safer reduction of unnecessary medicines (“deprescribing”), and helping oncology specialists personalise cancer treatment based on how a patient’s body processes medicines. By combining AI, clinical expertise and strong privacy protections, AIM-SAFE aims to make healthcare safer and more sustainable across Europe.
CPE’s role in the project
CPE plays an important role in ensuring that AIM-SAFE remains patient-centred, trustworthy and accessible. CPE supports the co-design of the project’s AI tools by helping organise workshops with patients, clinicians and other stakeholders, ensuring that patient perspectives and real-world needs are reflected in the system’s development. CPE also leads training and awareness activities on trustworthy AI in healthcare, developing educational toolkits and materials to help patients, healthcare professionals and stakeholders understand and safely use AI-supported clinical tools.
- University Hospital of Southern Denmark UHSD, Denmark
- University of Geneva UNIGE, Switzerland
- Hôpitaux Universitaires de Genève HUG, Switzerland
- Leki.pl sp. z o. o. LEKI, Poland
- Centre Hospitalier Universitaire de Toulouse CHU, France
- Novelcore NVCR, Greece
- Organisation Europeenne Pour La Recherche Nucleaire CERN, Switzerland
- Agencia Estatal Consejo Superior de Investigaciones Científicas CSIC, Spain
- Ecole Polytechnique Fédérale de Lausanne EPFL, Switzerland
- Sheffield Hallam University SHU, United Kingdom
- Ludwig-Maximilians-Universitaet Muenchen, Germany
- TriNetX Europe NV TNX, Belgium
- The Royal Marsden National Health Service Trust RMH, United Kingdom
- Limited liability Company Knowledgator Engineering KG, Ukraine
- European Molecular Biology Laboratory EMBL, Germany
- Technical University of Munich TUM, Germany
- Apheris AI GmbH, Germany
- Universitat de Barcelona UB, Spain
- University Medical Center Groningen UMCG, Netherlands
- Agora Labs AL, Italy
- Korea Advanced Institute of Science & Technology KAIST, South Korea
- Jagiellonian University Medical College UJ, Poland
- The European Geriatric Medicine Society EuGMS, Belgium
- University of Vienna UNIVIE, Austria
- University of Liverpool UoL, United Kingdom
- Cancer Patients Europe CPE, Belgium
Type of Action
HORIZON-HLTH
Funding
16,665,156.25 €
Project start date
1 June 2026
Project end date
31 May 2030
Website
Coming soon!
Social media links
Coming soon!
Lead Partner
University Hospital of Southern Denmark, Denmark
Focus Area
Generative AI, Federated learning, Small Language Models, Multi-agent clinical reasoning, Multimodal biomedical data, explainable AI, geriatrics, oncology, Retrieval Augmented Generation
Project Logo
